News items related to:
-
Paxlovid in the post pandemic world
The World Health Organization (WHO) recently declared that COVID-19 is “…now an established and ongoing health issue which no longer...
-
Hurdles and opportunities for Hepatitis C treatment in Thailand
Kularb Dangtong is the leader of a comprehensive HIV continuum of care center (CCC Center) in Thailand. CCC Centers are...
-
Patent-free, low-cost vaccines highly protective against severe COVID
A new analysis of 390,459 participants assessing 14 different COVID-19 vaccines has identified no significant difference in efficacy against both symptomatic and severe...
-
TNP+ opposes patent claims on Lenacapavir
TNP+, MMA’s partner in Thailand, has filled an opposition against Markush patent claims on lenacapavir, a new, long-acting antiretroviral drug,...
-
In times of peace and in times of war: 100% LIFE outstanding work in Ukraine
After two years of the worst pandemic in recent history, 2022 marked an extra tragic event in the history of...
-
GSIPA2M – Day 2
Welcome to Day 2 of GISPA2M 2022! Plenary III – Big Pharma’s multiverse of Madness Andrew Hill, University of Liverpool,...
-
GSIPA2M – Day 1
Welcome to the first day of 2022 GSIPA2M – The Pandemic Edition: Reclaiming Access Sergiy Kondratyuk, ITPC Global, Ukraine Sergiy...
-
GSIPA2M 2022 – The Pandemic Edition: Reclaiming Access
Civil Society from across the globe will gather in Istanbul from the 19th to the 21st of July 2022 for...
-
Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline
July 1, 2022 – A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global...
-
Médecins du Monde challenges patents on COVID-19 vaccine
Médecins du Monde (MdM), a global medical humanitarian organization, has exposed Pfizer/BioNTechs’s patent abuse on the COVID-19 vaccine by challenging...
-
Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Formulations?
Long-Acting Formulations (LAFs) have the potential to make treatment for hepatitis C (HCV) and tuberculosis (TB) easier to adhere to,...
-
COVID-19 – entering year three of normalizing profit over life
March 2022 marked the beginning of the third year of the COVID-19 pandemic. The status quo hasn’t changed: as pharmaceutical...
